Exact Sciences
EXAS
#1154
Rank
A$29.02 B
Marketcap
A$152.97
Share price
-0.07%
Change (1 day)
57.59%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

Revenue for Exact Sciences (EXAS)

Revenue in 2025 (TTM): A$4.79 Billion

According to Exact Sciences's latest financial reports the company's current revenue (TTM ) is A$4.66 Billion. In 2024 the company made a revenue of A$4.43 Billion an increase over the revenue in the year 2023 that were of A$3.66 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exact Sciences from 2001 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) A$4.79 B8.2%
2024 A$4.43 B20.89%
2023 A$3.66 B19.79%
2022 A$3.06 B25.66%
2021 A$2.43 B25.67%
2020 A$1.93 B54.97%
2019 A$1.25 B94.01%
2018 A$0.64 B89.35%
2017 A$0.34 B147.13%
2016 A$0.13 B154.67%
2015 A$54.13 M2364.08%
2014 A$2.19 M-52.71%
2013 A$4.64 M16.5%
2012 A$3.98 M-1.78%
2011 A$4.06 M-22.83%
2010 A$5.26 M-0.67%
2009 A$5.29 M
2007 A$3.35 M-44.29%
2006 A$6.02 M3.74%
2005 A$5.8 M-8.92%
2004 A$6.37 M63.4%
2003 A$3.9 M145.14%
2002 A$1.59 M1497.22%
2001 A$0.09 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Myriad Genetics
MYGN
A$1.24 B-73.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Antares Pharma
ATRS
A$0.27 B-94.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Veracyte
VCYT
A$0.74 B-83.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Biocept
BIOC
-A$5.21 Million-100.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$71.93 B 1,442.00%๐Ÿ‡ซ๐Ÿ‡ท France